The promise and challenges of pharmacogenomics in psychiatry

Pharmacogenomics (PGx) is an expanding field within precision medicine that is poised to play a crucial role in optimising patient outcomes, particularly in the realm of psychiatry. The remission rate for the initial antidepressant prescribed in the Sequenced Treatment Alternatives to Relieve Depre...

Full description

Saved in:
Bibliographic Details
Main Authors: Elaine Ah Gi Lo, Yi Min Wan, Cyrus Su Hui Ho
Format: Article
Language:English
Published: Academy of Medicine Singapore 2024-12-01
Series:Annals, Academy of Medicine, Singapore
Online Access:https://annals.edu.sg/the-promise-and-challenges-of-pharmacogenomics-in-psychiatry/
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pharmacogenomics (PGx) is an expanding field within precision medicine that is poised to play a crucial role in optimising patient outcomes, particularly in the realm of psychiatry. The remission rate for the initial antidepressant prescribed in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) trial was only approximately 30%, underscoring the need for more personalised approaches to prescribing.1 For psychiatric patients who may show resistance towards pharmacotherapy, PGx offers promise in reducing adverse effects and enhancing therapeutic efficacy. Personalised pharmacotherapy provides reassurance and potentially mitigates the nocebo effects and somatic symptom exacerbation that are prevalent among these patients.
ISSN:2972-4066